Acer Therapeutics Stock Working Capital
| ACERDelisted Stock | USD 0.84 0.02 2.33% |
Acer Therapeutics fundamentals help investors to digest information that contributes to Acer Therapeutics' financial success or failures. It also enables traders to predict the movement of Acer Stock. The fundamental analysis module provides a way to measure Acer Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acer Therapeutics stock.
Acer |
Acer Therapeutics Company Working Capital Analysis
Acer Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Acer Therapeutics Working Capital | (15.44 M) |
Most of Acer Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acer Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Acer Therapeutics has a Working Capital of (15.44 Million). This is 103.63% lower than that of the Pharmaceuticals sector and 102.87% lower than that of the Health Care industry. The working capital for all United States stocks is 101.04% higher than that of the company.
Acer Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acer Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acer Therapeutics could also be used in its relative valuation, which is a method of valuing Acer Therapeutics by comparing valuation metrics of similar companies.Acer Therapeutics is currently under evaluation in working capital category among its peers.
Acer Fundamentals
| Return On Equity | -4.73 | |||
| Return On Asset | -0.65 | |||
| Current Valuation | 52.01 M | |||
| Shares Outstanding | 24.46 M | |||
| Shares Owned By Insiders | 13.78 % | |||
| Shares Owned By Institutions | 29.91 % | |||
| Number Of Shares Shorted | 493.55 K | |||
| Price To Earning | (7.40) X | |||
| Price To Book | 17.26 X | |||
| Price To Sales | 174.52 X | |||
| Gross Profit | 1.26 M | |||
| EBITDA | (24.81 M) | |||
| Net Income | (26.24 M) | |||
| Cash And Equivalents | 14.47 M | |||
| Cash Per Share | 0.91 X | |||
| Total Debt | 11.86 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.87 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (30.25 M) | |||
| Short Ratio | 2.87 X | |||
| Earnings Per Share | (1.98) X | |||
| Target Price | 1.5 | |||
| Number Of Employees | 30 | |||
| Beta | 0.44 | |||
| Market Capitalization | 22.02 M | |||
| Total Asset | 11.62 M | |||
| Retained Earnings | (140.75 M) | |||
| Working Capital | (15.44 M) | |||
| Current Asset | 6.61 M | |||
| Current Liabilities | 5.62 M | |||
| Z Score | -24.48 | |||
| Annual Yield | 0.04 % | |||
| Net Asset | 11.62 M |
About Acer Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acer Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acer Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acer Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acer Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acer Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acer Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Acer Stock
| 0.43 | MSFT | Microsoft Aggressive Push | PairCorr |
| 0.36 | PG | Procter Gamble Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Acer Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acer Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acer Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acer Therapeutics to buy it.
The correlation of Acer Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acer Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acer Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acer Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |